Takeda Lays Out Teva JV Impact, Confirms Blopress Transfer
This article was originally published in PharmAsia News
Takeda has identified its first mature products to be transferred next April to a new joint venture with Teva, in a transaction it expects to be cash flow accretive next fiscal year despite an initial hit on revenues and operating profit.
You may also be interested in...
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.